Anne B Young

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease
    Anthone W Dunah
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Center for Aging, Genetics and Neurodegeneration, Charlestown, MA 02129, USA
    Science 296:2238-43. 2002
  2. ncbi Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases
    Ruth A Bodner
    Center for Cancer Research, Massachusetts Institute of Technology, Room E18-505, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 103:4246-51. 2006
  3. ncbi Huntingtin in health and disease
    Anne B Young
    Neurology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Invest 111:299-302. 2003
  4. ncbi A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo
    Xiaoqian Zhang
    Department of Biochemistry, Boston University Medical School, Boston, MA 02118, USA
    Proc Natl Acad Sci U S A 102:892-7. 2005
  5. ncbi Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1
    Birgit Zucker
    Department of Neurology, MassGeneral Institute for Neurodegenerative Diseases, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    Hum Mol Genet 14:179-89. 2005
  6. ncbi Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation
    Ruth Luthi-Carter
    MassGeneral Institute for Neurodegenerative Diseases, B114-2000, 114 16th Street, Charlestown, MA 02129-4404, USA
    Neurobiol Dis 14:624-36. 2003
  7. ncbi Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology
    George J Yohrling
    Department of Neurology, Center for Aging, Genetics, and Neurodegeneration, Massachusetts General Hospital, 114 16th Street, B114-2000, Charlestown, MA 02129-4404, USA
    Brain Res Mol Brain Res 119:28-36. 2003
  8. ncbi A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse
    Vanita Chopra
    Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 104:16685-9. 2007
  9. ncbi Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease
    Boris S Spektor
    Department of Neurology and Center for Aging, Genetics, and Neurodegeneration, Neurology/B114-2001, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129-4404, USA
    Brain Res Mol Brain Res 102:118-28. 2002
  10. ncbi Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease
    Edmond Y W Chan
    Center for Molecular Medicine and Therapeutics, Department of Medical Genetics, Children's and Women's Hospital, University of British Columbia, Vancouver, British Columbia, Canada, V5H 4H4
    Hum Mol Genet 11:1939-51. 2002

Research Grants

  1. METABOTROPIC GLUTAMATE RECEPTORS IN NEURODEGENERATION
    Anne Young; Fiscal Year: 2007

Collaborators

Detail Information

Publications20

  1. ncbi Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease
    Anthone W Dunah
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Center for Aging, Genetics and Neurodegeneration, Charlestown, MA 02129, USA
    Science 296:2238-43. 2002
    ..Understanding these early molecular events in HD may provide an opportunity to interfere with the effects of mutant huntingtin before the development of disease symptoms...
  2. ncbi Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases
    Ruth A Bodner
    Center for Cancer Research, Massachusetts Institute of Technology, Room E18-505, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
    Proc Natl Acad Sci U S A 103:4246-51. 2006
    ....
  3. ncbi Huntingtin in health and disease
    Anne B Young
    Neurology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Clin Invest 111:299-302. 2003
  4. ncbi A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo
    Xiaoqian Zhang
    Department of Biochemistry, Boston University Medical School, Boston, MA 02118, USA
    Proc Natl Acad Sci U S A 102:892-7. 2005
    ..The aggregation inhibitors identified in this screen represent four primary chemical scaffolds and are strong lead compounds for the development of therapeutics for human polyQ diseases...
  5. ncbi Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1
    Birgit Zucker
    Department of Neurology, MassGeneral Institute for Neurodegenerative Diseases, Massachusetts General Hospital and Harvard Medical School, Boston 02129, USA
    Hum Mol Genet 14:179-89. 2005
    ....
  6. ncbi Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation
    Ruth Luthi-Carter
    MassGeneral Institute for Neurodegenerative Diseases, B114-2000, 114 16th Street, Charlestown, MA 02129-4404, USA
    Neurobiol Dis 14:624-36. 2003
    ..Taken together, these data demonstrate multiple levels of NMDA receptor dysregulation, including abnormalities in mRNA expression levels, receptor stoichiometry, protein phosphorylation, and receptor trafficking...
  7. ncbi Analysis of cellular, transgenic and human models of Huntington's disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology
    George J Yohrling
    Department of Neurology, Center for Aging, Genetics, and Neurodegeneration, Massachusetts General Hospital, 114 16th Street, B114-2000, Charlestown, MA 02129-4404, USA
    Brain Res Mol Brain Res 119:28-36. 2003
    ..These findings implicate abnormalities in dopamine neurotransmission in HD and may provide new insights into targets for pharmacotherapy...
  8. ncbi A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse
    Vanita Chopra
    Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Proc Natl Acad Sci U S A 104:16685-9. 2007
    ..C2-8 provides an essential tool to help elucidate mechanisms of neurodegeneration in HD and a therapeutic lead for further optimization and development...
  9. ncbi Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease
    Boris S Spektor
    Department of Neurology and Center for Aging, Genetics, and Neurodegeneration, Neurology/B114-2001, Massachusetts General Hospital, 114 16th Street, Charlestown, MA 02129-4404, USA
    Brain Res Mol Brain Res 102:118-28. 2002
    ..Understanding the functional bases for these effects may further elucidate the complex pathophysiology of Huntington's disease...
  10. ncbi Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease
    Edmond Y W Chan
    Center for Molecular Medicine and Therapeutics, Department of Medical Genetics, Children's and Women's Hospital, University of British Columbia, Vancouver, British Columbia, Canada, V5H 4H4
    Hum Mol Genet 11:1939-51. 2002
    ..Furthermore, our findings suggest that short N-terminal fragments of mutant htt might be responsible for the gene expression alterations observed in human HD brain...
  11. ncbi Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects
    Ruth Luthi-Carter
    Center for Aging, Genetics and Neurodegeneration, Massachusetts General Hospital, Charlestown, MA 02129-4404, USA
    Hum Mol Genet 11:1927-37. 2002
    ..These results demonstrate that some of the gene expression effects of expanded polyglutamine proteins occur independently of protein context...
  12. ncbi Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain
    Ruth Luthi-Carter
    Center for Aging, Genetics and Neurodegeneration, Massachusetts General Hospital, Charlestown, MA 02129-4404, USA
    Hum Mol Genet 11:1911-26. 2002
    ..The complete dataset is available at www.neumetrix.info...
  13. ncbi Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease
    Tiago Fleming Outeiro
    Alzheimer s Research Unit, MGH, Harvard Medical School, CNY 114, 16th Street, Charlestown, MA 02129, USA
    Science 317:516-9. 2007
    ..Furthermore, the inhibitors protected against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease. The results suggest a link between neurodegeneration and aging...
  14. ncbi Myopathy as a first symptom of Huntington's disease in a Marathon runner
    Christoph M Kosinski
    Department of Neurology, University Hospital RWTH Aachen, Germany
    Mov Disord 22:1637-40. 2007
    ..Challenging skeletal muscle by excessive training might have disclosed myopathy in HD even years before the appearance of other neurological symptoms...
  15. ncbi Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragments
    Myra Coufal
    Massachusetts Institute of Technology, Cambridge, MA, USA
    J Biomol Screen 12:351-60. 2007
    ..These compounds were subjected to a functional assay, which yielded a lead compound that rescues cells from induced mutant polyglutamine toxicity...
  16. ncbi Regional and cellular gene expression changes in human Huntington's disease brain
    Angela Hodges
    Department of Psychological Medicine, Wales College of Medicine and School of Biosciences, Cardiff University, Heath Park, Cardiff CF14 4XN, Wales, UK
    Hum Mol Genet 15:965-77. 2006
    ..These data from bona fide HD brains comprise an important reference for hypotheses related to HD and other neurodegenerative diseases...
  17. ncbi Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice
    Anil Kachroo
    MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02129, USA
    J Neurosci 25:10414-9. 2005
    ..These data also strengthen a rationale for pursuing a combinational drug strategy for enhancing the antiparkinsonian effects of A2A and mGlu5 antagonists...
  18. ncbi Interrater agreement in the assessment of motor manifestations of Huntington's disease
    Penelope Hogarth
    Oregon Health and Science University, Portland, Oregon 97239 3098, USA
    Mov Disord 20:293-7. 2005
    ..We expect these findings to translate to a similar level of interobserver agreement in the clinical trial setting involving experienced investigators examining live patients...
  19. ncbi Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset
    Nancy S Wexler
    Columbia University, 1051 Riverside Drive, New York, NY 10032, USA
    Proc Natl Acad Sci U S A 101:3498-503. 2004
    ..37), shared environment (0.22), and nonshared environment (0.41) variances, confirming that approximately 40% of the variance remaining in onset age is attributable to genes other than the HD gene and 60% is environmental...
  20. ncbi Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice
    Teresa Gomez-Isla
    Department of Neurology, University of Minnesota, Minneapolis, MN 55455, USA
    Neurobiol Aging 24:245-58. 2003
    ..Thus, high expression of mutant human alpha-synuclein resulted in a progressive motor and widespread CNS gliotic phenotype independent of dopaminergic dysfunction in the Tg5093 line...

Research Grants3

  1. METABOTROPIC GLUTAMATE RECEPTORS IN NEURODEGENERATION
    Anne Young; Fiscal Year: 2007
    ..For type specifications, see instructions on page 6.) RESEARCH GRANT TABLE OF CONTENTS Page Numbers Face Page 1 Description, ..